512 related articles for article (PubMed ID: 33515644)
1. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
[TBL] [Abstract][Full Text] [Related]
2. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
[TBL] [Abstract][Full Text] [Related]
3. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
4. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
5. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
[TBL] [Abstract][Full Text] [Related]
6. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
7. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
8. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
He F; Zhang P; Liu J; Wang R; Kaufman RJ; Yaden BC; Karin M
J Hepatol; 2023 Aug; 79(2):362-377. PubMed ID: 36996941
[TBL] [Abstract][Full Text] [Related]
9. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
Sydor S; Best J; Messerschmidt I; Manka P; Vilchez-Vargas R; Brodesser S; Lucas C; Wegehaupt A; Wenning C; Aßmuth S; Hohenester S; Link A; Faber KN; Moshage H; Cubero FJ; Friedman SL; Gerken G; Trauner M; Canbay A; Bechmann LP
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00131. PubMed ID: 32352707
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet.
Miura K; Ohnishi H; Morimoto N; Minami S; Ishioka M; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Isoda N; Yamamoto H
Cancer Sci; 2019 Feb; 110(2):771-783. PubMed ID: 30520543
[TBL] [Abstract][Full Text] [Related]
11. Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling.
Sun L; Beggs K; Borude P; Edwards G; Bhushan B; Walesky C; Roy N; Manley MW; Gunewardena S; O'Neil M; Li H; Apte U
Am J Physiol Gastrointest Liver Physiol; 2016 Jul; 311(1):G91-G104. PubMed ID: 27151938
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
13. Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure.
Torres S; Baulies A; Insausti-Urkia N; Alarcón-Vila C; Fucho R; Solsona-Vilarrasa E; Núñez S; Robles D; Ribas V; Wakefield L; Grompe M; Lucena MI; Andrade RJ; Win S; Aung TA; Kaplowitz N; García-Ruiz C; Fernández-Checa JC
Gastroenterology; 2019 Aug; 157(2):552-568. PubMed ID: 31029706
[TBL] [Abstract][Full Text] [Related]
14. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
[No Abstract] [Full Text] [Related]
15. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
[TBL] [Abstract][Full Text] [Related]
16. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
18. Sex-dependent effects on gut microbiota regulate hepatic carcinogenic outcomes.
Xie G; Wang X; Zhao A; Yan J; Chen W; Jiang R; Ji J; Huang F; Zhang Y; Lei S; Ge K; Zheng X; Rajani C; Alegado RA; Liu J; Liu P; Nicholson J; Jia W
Sci Rep; 2017 Mar; 7():45232. PubMed ID: 28345673
[TBL] [Abstract][Full Text] [Related]
19. Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet.
Chun HJ; Shim YJ; Kwon YH
J Nutr Biochem; 2022 Feb; 100():108869. PubMed ID: 34563665
[TBL] [Abstract][Full Text] [Related]
20. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
